Company intelligence / Profile preview
Atridia Pty Ltd
Sydney, New South Wales, Australiaatridia.com.au ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Atridia has several approved drugs in China including IL-17A inhibitors (approved August 20, 2024), PDL1 inhibitors (approved February 28, 2023), and AR antagonists (approved June 28, 2022). Their drug Adebrelimab is marketed for small cell lung cancer and in Phase III for non-small cell lung cancer.
- Therapeutic areas
- GastroenterologyOncologyHematology
- Modalities
- Monoclonal antibodyAntibody drug conjugate (ADC)Bispecific antibodyAntibody fusion proteinsSmall molecule drug
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Jiangsu Hengrui Medicine Co., Ltd.
Beyond the preview
Go deeper on Atridia Pty Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atridia Pty Ltd.